Skip to main content
Top
Published in: Breast Cancer Research and Treatment 3/2018

Open Access 01-12-2018 | Epidemiology

Time to death in breast cancer patients as an indicator of treatment response

Authors: Steven A. Narod, Vasily Giannakeas, Victoria Sopik

Published in: Breast Cancer Research and Treatment | Issue 3/2018

Login to get access

Abstract

Purpose

To describe the mortality experience of women who die of breast cancer in the 20-year period post-diagnosis using various metrics, including annual mortality rates, Kaplan–Meier survival curves and time-to-death histograms.

Methods

We generated three visual representations of SEER-based and hospital-based breast cancer patient cohorts using three different metrics of mortality.

Results

The greatest impact of most prognostic factors was on the probability of latent metastases present after treatment, but for some factors the primary impact was on the time to death for those women with metastases.

Conclusions

The use of time-to-death statistics to display mortality benefits for treated versus untreated women helps facilitate the distinction between treatments which increase the likelihood of cure and treatments that delay cancer growth.
Appendix
Available only for authorised users
Literature
1.
go back to reference Schairer C, Mink PJ, Carroll L, Devesa SS (2004) Probabilities of death from breast cancer and other causes among female breast cancer patients. J Natl Cancer Inst 96:1311–1321CrossRef Schairer C, Mink PJ, Carroll L, Devesa SS (2004) Probabilities of death from breast cancer and other causes among female breast cancer patients. J Natl Cancer Inst 96:1311–1321CrossRef
2.
go back to reference Taylor R, Davis P, Boyages J (2003) Long-term survival of women with breast cancer in New South Wales. Eur J Cancer 39:215–222CrossRef Taylor R, Davis P, Boyages J (2003) Long-term survival of women with breast cancer in New South Wales. Eur J Cancer 39:215–222CrossRef
3.
go back to reference Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687–1717CrossRef Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687–1717CrossRef
4.
go back to reference Dent R, Hanna WM, Trudeau M, Rawlinson E, Sun P, Narod SA (2009) Pattern of metastatic spread in triple-negative breast cancer. Breast Cancer Res Treat 115:423–428CrossRef Dent R, Hanna WM, Trudeau M, Rawlinson E, Sun P, Narod SA (2009) Pattern of metastatic spread in triple-negative breast cancer. Breast Cancer Res Treat 115:423–428CrossRef
Metadata
Title
Time to death in breast cancer patients as an indicator of treatment response
Authors
Steven A. Narod
Vasily Giannakeas
Victoria Sopik
Publication date
01-12-2018
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 3/2018
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-018-4935-3

Other articles of this Issue 3/2018

Breast Cancer Research and Treatment 3/2018 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine